ATLANTA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks’ digital channels, today announced that its financial results for the third quarter ending September 30, 2024 will be released on November 6, 2024, after market close. The results will be discussed via conference call at 5:00 PM ET / 2:00 PM PT. The company invites investors to join a live audio webcast at http://ir.cardlytics.com/ or to dial-in by registering at this link. A replay will be available ...

ATLANTA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cardlytics, Inc. (NASDAQ: CDLX), an advertising platform in banks' digital channels, today announced that, on August 19, 2024, the Compensation Committee of Cardlytics' Board of Directors granted an aggregate of 49,900 restricted stock units of Cardlytics to seven newly hired employees. The restricted stock units were granted as material inducements to employment with Cardlytics in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Cardlytics ...

Core Viewpoint - Cardlytics, Inc. has faced significant scrutiny following a substantial miss in its Q2 2024 financial results, attributed to known technology issues that have persisted for at least one to two quarters [2]. Investigation Details - Cardlytics previously claimed that its technology initiatives were yielding positive results, but the recent financial report contradicted this assertion [2]. - The company reported a significant shortfall in its financial projections from three months prior, leading to a decline in stock value [2]. - Management acknowledged that the technology issues had been recognized internally for a quarter or two before the public disclosure [2]. Next Steps - Investors who have information related to the investigation or who purchased Cardlytics securities are encouraged to participate in the investigation [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in their legal actions [4]. - The firm has a history of representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for clients [5].

LOS ANGELES, Aug. 14, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or "the Company") (NASDAQ: CDLX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cardlytics claimed to the market that its technology initiatives were "really ...

SAN FRANCISCO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Cardlytics, Inc. (NASDAQ: CDLX) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Visit: www.hbsslaw.com/investor-fraud/cdlx Contact the Firm Now: CDLX@hbsslaw.com 844-916-0895 Investigation Into Cardlytics, Inc. (CDLX): Cardlytics Inc. is facing scrutiny from prominent shareholder rights firm Hagens B ...

ATLANTA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ: CDLX) complied with federal securities laws. On August 7, 2024, Cardlytics reported financial results for its second quarter ended June 30, 2024, including a decrease of 9% year-over-year in revenue, stating "our results were challenged by slower-than-anticipated billings growth coupled with higher consumer incentives." Following this news, the price of the Compa ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX) on behalf of Cardlytics stockholders. Our investigation concerns whether Cardlytics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On August 7, 2024, Cardlytics announced its second quarter 202 ...

Core Insights - Johnson Fistel, LLP is investigating potential violations of securities laws by Cardlytics, Inc. and its executives regarding misrepresentation or failure to disclose adverse information to investors [1][3] - Cardlytics reported a 9% year-over-year decrease in revenue to $69.6 million and a 3% decline in adjusted contribution to $36.4 million for Q2 2024 [3] - Following the financial results announcement, Cardlytics' stock dropped 56% in pre-market trading on August 8, 2024 [3] Investigation Details - The investigation focuses on the losses suffered by investors and the possibility of recovering those losses under federal securities laws [1][3] - Individuals with nonpublic information about Cardlytics are encouraged to assist in the investigation or consider the SEC Whistleblower program, which may offer rewards for original information leading to successful recovery [4] Company Background - Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado, representing individual and institutional investors in securities class action lawsuits [5]

Cardlytics, Inc. (NASDAQ:CDLX) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Nick Lynton - Chief, Legal & Privacy Officer Jack Klinck - Chairperson of the Board Amit Gupta - Chief Operating Officer Alexis DeSieno - Chief Financial Officer Conference Call Participants Jaeson Schmidt - Lake Street Capital Markets Kyle Peterson - Needham Luke Horton - Northland Capital Markets Jason Kreyer - Craig-Hallum Operator Good day, and thank you for standing by. Welcome to the Cardlyti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-38386 CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware ...